论文信息 - Evolution of biomarker qualification at the health authorities - 字舞流文

Evolution of biomarker qualification at the health authorities

By streamlining the qualification process for biomarkers, coordinated protocols recently implemented at the different regulatory agencies can facilitate progress and provide impetus to novel biomarker discovery and validation.

Federico Goodsaid | Marisa Papaluca | F. Goodsaid | M. Papaluca

[1] A. Hunter,et al. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. , 2008, Drug discovery today.

[2] D Amakye,et al. A Prototypical Process for Creating Evidentiary Standards for Biomarkers and Diagnostics , 2008, Clinical pharmacology and therapeutics.

[3] William E. Patrick. The Food and Drug Administration , 1988 .

[4] Stephen A. Williams,et al. The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development , 2009, Clinical pharmacology and therapeutics.

[5] Federico M Goodsaid,et al. Strategic paths for biomarker qualification. , 2008, Toxicology.